MAOR-GP
Maor GP, a Luxembourg based co-investment fund dedicated to Israeli-related technology, is proud to announce the final closing of its first fund, Maor 1, at its target close to 100M$.
Maor 1 is the first Luxembourg-based Israeli tech fund created to facilitate access of European investors and in particular European Family offices to the Israeli Technology ecosystem and opportunities.
Rothschild & Co is a cornerstone investor in the fund comprising mainly European Family offices.
Maor is a Hebrew name and our free translation of it is Explorer.
Maor’s mission is to explore and invest in the leading technology ecosystem of Israel while bridging the gap between Europe and Israel.
With a very strong local team in Israel and a very strong corporate network in Europe, Maor can directly source the best Israeli startups and help them grow in Europe, find partners, clients or acquisition targets and eventually create value for our investors.
We, at Maor thank all our Limited Partners for their trust and support in this exciting venture.
For more information, please check our internet site www.maorinvestments.com or contact IR@maorinvestments.com .
MAOR GP
19, Rue de Bitbourg
L-1273 Luxembourg
Luxembourg
View source version on businesswire.com: https://www.businesswire.com/news/home/20190621005015/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MA-RENAGADE-THERAPEUTICS27.4.2024 02:10:34 CEST | Press release
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
NY-HCLTECH26.4.2024 22:07:31 CEST | Press release
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY
KINAXIS-INC.26.4.2024 18:04:28 CEST | Press release
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions
VERTEX-PHARMA26.4.2024 17:44:28 CEST | Press release
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
SUZANO-S.A.26.4.2024 17:23:27 CEST | Press release
Suzano 2023 annual report on Form 20-F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom